Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of autologous anti-CD19 CAR T-cells.

Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 ...

Discover how HT-SPR evaluation has been used for Fc gamma receptor binding.

H eightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some ...

Fcγ receptors (FcγRs) classically modulate intracellular signaling on binding of the Fc region of IgG in immune response cells. How FcγR and their ligands affect cardiovascular health and disease has ...

Fc γ receptor RI (FcγRI) has the highest affinity for IgG1-type monoclonal antibodies within the Fc γ receptor family (FcγRs). The surface of immune cells such as monocytes, macrophages, dendritic ...

Fc receptors (FcRs) belong to the ITAM-associated receptor family. FcRs control the humoral and innate immunity which are essential for appropriate responses to infections and prevention of chronic ...

SCOTTSDALE, Ariz. — A novel therapeutic approach targeting the neonatal fragment crystallizable receptor may have implications across a number of rheumatology disease states, according to a ...

Turning to neonatal Fc receptors, Wright noted that these therapies are not targeting cytokines, but the “recycling” that occurs to prevent degradation of IgG.

Most human monoclonal antibodies isolated from sera are IgG1 antibodies. Neutralizing capacity aside, IgG1 is the joint-most potent activator of Fc gamma receptors on immune cells, alongside IgG3.